Compare HNVR & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | NERV |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.4M | 166.4M |
| IPO Year | 2022 | 2014 |
| Metric | HNVR | NERV |
|---|---|---|
| Price | $26.43 | $3.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $24.50 | $10.50 |
| AVG Volume (30 Days) | 29.2K | ★ 127.7K |
| Earning Date | 04-27-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | $35.49 | N/A |
| Revenue Next Year | $8.61 | N/A |
| P/E Ratio | $33.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $2.01 |
| 52 Week High | $27.94 | $12.46 |
| Indicator | HNVR | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 30.08 |
| Support Level | $26.41 | N/A |
| Resistance Level | $27.89 | $4.73 |
| Average True Range (ATR) | 0.70 | 0.29 |
| MACD | -0.13 | -0.13 |
| Stochastic Oscillator | 15.79 | 1.37 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.